Disodium Pamidronate
Generic medicine reference
Not yet clinically reviewed
This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.
Overview
Disodium Pamidronate is a bisphosphonate, inhibits bone resorption and thus reduces bone turn over. Disodium Pamidronate is used in the treatment of bone disorders in which excessive bone resorption is a problem, such as Paget's disease of bone and osteoporosis. Disodium Pamidronate is also used as an adjunct in severe hypercalcemic conditions especially associated with malignancies.
Indications
Disodium Pamidronate is primarily indicated in conditions like Hypercalcemia due to malignancy, Hypercalcemia of malignancy, Osteolytic bone metastases, Osteolytic lesions and bone pain, Paget's disease of bone, Sedation with amnesia.
Contraindications
Disodium Pamidronate is contraindicated in conditions like Pregnancy,Breast feeding.
Side Effects
The symptomatic adverse reactions produced by Disodium Pamidronate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Anorexia, Diarrhea, Fever, Myalgia, Constipation, Insomnia, Abdominal pain, Rashes, Confusion, Pruritus, Lethargy, Hallucination, Dyspepsia, Malaise, Hypotension, Somnolence, Flushing, Arthralgia, Nausea and vomiting, Muscle cramps, Influenza like syndrome, Agitation, Conjunctivitis, Rigors, Seizures, Transient rise in body temperature, Transient bone pain, Local reaction at injection site, Thrombophilia.
Warnings
Disodium Pamidronate should be used with caution in patients with cardiac disease with renal impairment---monitor renal function in renal disease or predisposition to renal impairment (e.g. in multiple myeloma or tumor induced hypercalcemia); cardiac disease (especially in elderly); previous thyroid surgery (risk of hypocalcemia); monitor serum electrolyte, calcium and phosphate---possibility of convulsions due to electrolyte changes; avoid concurrent use with other bisphosphonate. DRIVING: Patients should be warned against driving or operating machinery immediately after treatment (somnolence or dizziness may occur)
High Risk Groups
Drug should not be given to Paediatrics, and Pregnant Mothers. If prescribing authority justifies the benefits of the drug against the possible damages, he/she should reevaluate them and consult the reference material and previous studies.
Adult Dosage
30 mg (30 (30)) 24 hourly IV — For paget disease: administered as a 4-hour infusion on 3 consecutive days for a total dose of 90 mg.
60 to 90 mg (75 (75)) As recommended. IV — Moderate hypercalcemia: Given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours.
Child Dosage
No child dosage information is recorded for this medicine yet.
Neonatal Dosage
No neonatal dosage information is recorded for this medicine yet.
Drug Interactions
No data regarding the interactions of Disodium Pamidronate was found.
Storage
No storage information is recorded for this medicine yet.
Available Brands in Pakistan
No brands are recorded for this generic.